- Home
- TLPH vs PPBT Comparison
TLPH vs PPBT Comparison
Compare TLPH & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- PPBT
- Stock Information
- Founded
- TLPH 2005
- PPBT 2010
- Country
- TLPH United States
- PPBT Israel
- Employees
- TLPH N/A
- PPBT N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- PPBT Health Care
- Exchange
- TLPH Nasdaq
- PPBT Nasdaq
- Market Cap
- TLPH 11.1M
- PPBT 2.1M
- IPO Year
- TLPH 2011
- PPBT N/A
- Fundamental
- Price
- TLPH $0.98
- PPBT $0.60
- Analyst Decision
- TLPH Strong Buy
- PPBT Strong Buy
- Analyst Count
- TLPH 1
- PPBT 1
- Target Price
- TLPH $6.00
- PPBT $33.00
- AVG Volume (30 Days)
- TLPH 7.3M
- PPBT 2.9M
- Earning Date
- TLPH 11-12-2025
- PPBT 11-14-2025
- Dividend Yield
- TLPH N/A
- PPBT N/A
- EPS Growth
- TLPH N/A
- PPBT N/A
- EPS
- TLPH N/A
- PPBT N/A
- Revenue
- TLPH $27,000.00
- PPBT N/A
- Revenue This Year
- TLPH N/A
- PPBT N/A
- Revenue Next Year
- TLPH $14,533.26
- PPBT N/A
- P/E Ratio
- TLPH N/A
- PPBT N/A
- Revenue Growth
- TLPH N/A
- PPBT N/A
- 52 Week Low
- TLPH $0.38
- PPBT $0.53
- 52 Week High
- TLPH $1.20
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- TLPH 58.69
- PPBT 32.32
- Support Level
- TLPH N/A
- PPBT N/A
- Resistance Level
- TLPH $1.20
- PPBT $2.36
- Average True Range (ATR)
- TLPH 0.12
- PPBT 0.14
- MACD
- TLPH 0.01
- PPBT -0.10
- Stochastic Oscillator
- TLPH 81.67
- PPBT 25.54
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.